Evidence map›Paper›PMID 33556369›Full record

ArticleThe Journal of biological chemistry

Overexpression of TopBP1, a canonical ATR/Chk1 activator, paradoxically hinders ATR/Chk1 activation in cancer.

Kang Liu, Joshua D Graves, Fang-Tsyr Lin, Weei-Chin Lin

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in The Journal of biological chemistry. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. A small-molecule inhibitor of TopBP1 exerts anti-MYC activity and synergy with PARP inhibitors.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  4. Review
  5. Article
  6. Review
  7. USP13: Multiple Functions and Target Inhibition.Frontiers in cell and developmental biology · 2022
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Kang LiuSection of Hematology/Oncology, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.
Joshua D GravesSection of Hematology/Oncology, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.
Fang-Tsyr LinSection of Hematology/Oncology, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.
Weei-Chin LinSection of Hematology/Oncology, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas, USA. Electronic address: weeichil@bcm.edu.
Baylor College of Medicine · US

Funding

Tumor BiologyP30CA125123 · NCI · BAYLOR COLLEGE OF MEDICINE · PI Michael M Ittmann · 2007 to 2026
$73.9M
Virology CoreP30AI036211 · NIAID · BAYLOR COLLEGE OF MEDICINE · PI BUTEL, JANET S · 1994 to 2015
$21.7M
The ATM/E2F1 Pathway in DNA Damage and Growth ControlR01CA100857 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI LIN, WEEI-CHIN · 2004 to 2019
$4.8M
Novel therapeutics for targeting checkpoint dysfunction in cancerR01CA203824 · NCI · BAYLOR COLLEGE OF MEDICINE · PI FANG-TSYR LIN, WEEI-CHIN LIN · 2017 to 2026
$3.7M
Therapeutic Targeting of Oncogenic Stress in Cancer TreatmentR01CA138641 · NCI · BAYLOR COLLEGE OF MEDICINE · PI LIN, WEEI-CHIN · 2010 to 2014
$1.5M
BD Biosciences Special Order LSRIIS10RR024574 · NCRR · BAYLOR COLLEGE OF MEDICINE · PI LUMPKIN, ELLEN A · 2009 to 2009
$430k
NCI NIH HHS P30 CA125123NCI NIH HHS R01 CA100857NCI NIH HHS R01 CA138641NCI NIH HHS R01 CA203824NCRR NIH HHS S10 RR024574NIAID NIH HHS P30 AI036211
6 · The paper itself

Abstract

Topoisomerase IIβ-binding protein 1 (TopBP1) is involved in cellular replication among other functions and is known to activate ATR/Chk1 during replicative stress. TopBP1 is also expressed at high levels in many cancers. However, the impact of TopBP1 overexpression on ATR/Chk1 activation and cancer development has not been investigated. Here we demonstrate that the degree of ATR/Chk1 activation is regulated by TopBP1 in a biphasic, concentration-dependent manner in a nontransformed MCF10A cell line and several cancer cell lines, including H1299, MDA-MB468, and U2OS. At low levels, TopBP1 activates ATR/Chk1, but once TopBP1 protein accumulates above an optimal level, it paradoxically leads to lower activation of ATR/Chk1. This is due to the perturbation of ATR-TopBP1 interaction and ATR chromatin loading by excessive TopBP1. Overexpression of TopBP1 thus hinders the ATR/Chk1 checkpoint response, leading to the impairment of genome integrity as demonstrated by the cytokinesis-block micronucleus assay. In contrast, moderate depletion of TopBP1 by shRNA in TopBP1-overexpressing cancer cells enhanced ATR/Chk1 activation and S-phase checkpoint response after replicative stress. The clinical significance of these findings is supported by an association between TopBP1 overexpression and genome instability in many types of human cancer. Taken together, our study illustrates an unexpected relationship between the levels of TopBP1 and the final functional outcome and suggests TopBP1 overexpression as a new mechanism directly contributing to genomic instability during tumorigenesis.

Indexed as

Adaptor Proteins, Signal TransducingAtaxia Telangiectasia Mutated ProteinsCarrier ProteinsCell Cycle ProteinsCell Line, TumorCheckpoint Kinase 1ChromatinDNA-Binding ProteinsDNA DamageDNA ReplicationGene ExpressionGene Expression Regulation, NeoplasticHumansNuclear ProteinsPhosphorylationProtein KinasesAdaptor Proteins, Signal TransducingAtaxia Telangiectasia Mutated ProteinsATR protein, humanCarrier ProteinsCell Cycle ProteinsCheckpoint Kinase 1CHEK1 protein, humanChromatinDNA-Binding ProteinsNuclear ProteinsProtein KinasesTOPBP1 protein, humanATRChk1hormesisTopBP1

Identifiers

PMID33556369
PMCPMC7949146
OpenAlexW3126874575

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.